Please login to the form below

Not currently logged in
Email:
Password:

Alnylam

This page shows the latest Alnylam news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca and Ionis sign $3.6bn deal for eplontersen

AstraZeneca and Ionis sign $3.6bn deal for eplontersen

However, if approved, eplontersen will not have the ATTR market to itself and must compete with Pfizer’s Vyndaqel/Vyndamax (tafamidis) and Alnylam’s RNAi therapy Onpattro (patisiran).

Latest news

More from news
Approximately 19 fully matching, plus 46 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Editas Medicine adds to board of directors Editas Medicine adds to board of directors

    Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins. Cambridge, Massachusetts-based Editas Medicine has appointed Dr Akshay Vaishnaw to its board of directors. ... He has extensive clinical development experience, a passion for scientific excellence, and

  • VC firm expands team, appoints Genzyme and Lilly veterans VC firm expands team, appoints Genzyme and Lilly veterans

    The firm, which focuses on building healthcare companies, has appointed former executives from Genzyme, Lilly, ImClone and Alnylam to help it translate scientific innovation into new companies. ... Also joining Third Rock as venture partners are Daniel

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • EPG Health EPG Health

    Strategic planning - to ensure ongoing engagement and success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, GSK, HRA Pharma, Janssen, Leo Pharma, Lilly,

  • How do you define a biotech company?

    This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where 

  • Managing value: Why early asset development and commercialization is important

    For example, Alnylam Pharmaceuticals, with its lead product in Phase III, has a market capitalisation of $7.4 billion, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
Serious about sustainability?
Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...
How scientific storytelling can help Pharma cut through the noise
Rather than being afraid of storytelling, pharmaceutical firms should be embracing it. Because what scientific storytelling allows us to do is to communicate quickly and efficiently. It provides a shortcut...